02391nam 2200529 450 991081238330332120230803030624.01-78084-162-0(CKB)2670000000391287(EBL)1179620(OCoLC)851970656(SSID)ssj0001599917(PQKBManifestationID)16306388(PQKBTitleCode)TC0001599917(PQKBWorkID)14892429(PQKB)11462420(MiAaPQ)EBC1179620(Au-PeEL)EBL1179620(EXLCZ)99267000000039128720220517d2013 uy 0engur|n|---|||||txtccrAdvances in pulmonary neuroendocrine tumor management /editor, Kjell Öberg1st ed.London, England :Future Medicine Ltd.,[2013]©20131 online resource (101 p.)Description based upon print version of record.1-78084-164-7 Title page; Copyright page; Contents; Foreword. Advances in pulmonary neuroendocrine tumor management; 1. Classification; 2. Molecular imaging & peptide receptor radionuclide therapy; 3. Biotherapy: somatostatin analogs and IFN-α; 4. Typical and atypical bronchial carcinoid tumors; 5. Small-cell lung cancer and large-cell neuroendocrine tumors of the lung; 6. Thymic neuroendocrine tumors; 7. Algorithm for management of bronchopulmonary neuroendocrine tumors; IndexPulmonary neuroendocrine tumors (NETs) account for approximately one-quarter of all malignant lung cancers, the vast majority being represented by small-cell lung carcinoma. This thorough overview of this challenging field from international experts explores the various existing and emerging treatment options across the NET spectrum together with approaches to diagnosis and monitoring of disease.Neuroendocrine tumorsTreatmentLungsTumorsTreatmentNeuroendocrine tumorsTreatment.LungsTumorsTreatment.616.99424Öberg KjellMiAaPQMiAaPQMiAaPQBOOK9910812383303321Advances in pulmonary neuroendocrine tumor management4038750UNINA